319 related articles for article (PubMed ID: 37430086)
21. A novel siRNA validation system for functional screening and identification of effective RNAi probes in mammalian cells.
Hung CF; Lu KC; Cheng TL; Wu RH; Huang LY; Teng CF; Chang WT
Biochem Biophys Res Commun; 2006 Aug; 346(3):707-20. PubMed ID: 16793020
[TBL] [Abstract][Full Text] [Related]
22. Knocking down disease: a progress report on siRNA therapeutics.
Wittrup A; Lieberman J
Nat Rev Genet; 2015 Sep; 16(9):543-52. PubMed ID: 26281785
[TBL] [Abstract][Full Text] [Related]
23. Small interfering RNAs (siRNAs) based gene silencing strategies for the treatment of glaucoma: Recent advancements and future perspectives.
Naik S; Shreya AB; Raychaudhuri R; Pandey A; Lewis SA; Hazarika M; Bhandary SV; Rao BSS; Mutalik S
Life Sci; 2021 Jan; 264():118712. PubMed ID: 33159955
[TBL] [Abstract][Full Text] [Related]
24. Small interfering RNA: Discovery, pharmacology and clinical development-An introductory review.
Ranasinghe P; Addison ML; Dear JW; Webb DJ
Br J Pharmacol; 2023 Nov; 180(21):2697-2720. PubMed ID: 36250252
[TBL] [Abstract][Full Text] [Related]
25. [Research progress on the development of the strategies for siRNAs delivery in vivo].
Tang D; Mao A
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2012 Aug; 29(4):775-9. PubMed ID: 23016434
[TBL] [Abstract][Full Text] [Related]
26. Chemical modifications on siRNAs avoid Toll-like-receptor-mediated activation of the hepatic immune system in vivo and in vitro.
Broering R; Real CI; John MJ; Jahn-Hofmann K; Ickenstein LM; Kleinehr K; Paul A; Gibbert K; Dittmer U; Gerken G; Schlaak JF
Int Immunol; 2014 Jan; 26(1):35-46. PubMed ID: 24065781
[TBL] [Abstract][Full Text] [Related]
27. siRNAs and Viruses: The good, the Bad and the Way Forward.
Soobramoney C; Parboosing R
Curr Mol Pharmacol; 2022; 15(1):143-158. PubMed ID: 33881977
[TBL] [Abstract][Full Text] [Related]
28. siRNA delivery systems for cancer treatment.
Oh YK; Park TG
Adv Drug Deliv Rev; 2009 Aug; 61(10):850-62. PubMed ID: 19422869
[TBL] [Abstract][Full Text] [Related]
29. Designing highly active siRNAs for therapeutic applications.
Walton SP; Wu M; Gredell JA; Chan C
FEBS J; 2010 Dec; 277(23):4806-13. PubMed ID: 21078115
[TBL] [Abstract][Full Text] [Related]
30. Small interfering RNA-mediated gene suppression as a therapeutic intervention in hepatocellular carcinoma.
Hajiasgharzadeh K; Somi MH; Shanehbandi D; Mokhtarzadeh A; Baradaran B
J Cell Physiol; 2019 Apr; 234(4):3263-3276. PubMed ID: 30362510
[TBL] [Abstract][Full Text] [Related]
31. Development of RNAi technology for targeted therapy--a track of siRNA based agents to RNAi therapeutics.
Zhou Y; Zhang C; Liang W
J Control Release; 2014 Nov; 193():270-81. PubMed ID: 24816071
[TBL] [Abstract][Full Text] [Related]
32. Rational design and in vitro and in vivo delivery of Dicer substrate siRNA.
Amarzguioui M; Lundberg P; Cantin E; Hagstrom J; Behlke MA; Rossi JJ
Nat Protoc; 2006; 1(2):508-17. PubMed ID: 17406276
[TBL] [Abstract][Full Text] [Related]
33. Nonviral in vivo delivery of therapeutic small interfering RNAs.
Aigner A
Curr Opin Mol Ther; 2007 Aug; 9(4):345-52. PubMed ID: 17694447
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic siRNA: State-of-the-Art and Future Perspectives.
Friedrich M; Aigner A
BioDrugs; 2022 Sep; 36(5):549-571. PubMed ID: 35997897
[TBL] [Abstract][Full Text] [Related]
35. Development of RNA interference-based therapeutics and application of multi-target small interfering RNAs.
Li T; Wu M; Zhu YY; Chen J; Chen L
Nucleic Acid Ther; 2014 Aug; 24(4):302-12. PubMed ID: 24796432
[TBL] [Abstract][Full Text] [Related]
36. siRNA-Based Novel Therapeutic Strategies to Improve Effectiveness of Antivirals: An Insight.
Chatterjee K; Lakdawala S; Quadir SS; Puri D; Mishra DK; Joshi G; Sharma S; Choudhary D
AAPS PharmSciTech; 2023 Aug; 24(6):170. PubMed ID: 37566146
[TBL] [Abstract][Full Text] [Related]
37. Effective inhibition of hepatitis B virus replication by small interfering RNAs expressed from human foamy virus vectors.
Sun Y; Li Z; Li L; Li J; Liu X; Li W
Int J Mol Med; 2007 Apr; 19(4):705-11. PubMed ID: 17334648
[TBL] [Abstract][Full Text] [Related]
38. Recent progress in chemically modified siRNAs.
Gaglione M; Messere A
Mini Rev Med Chem; 2010 Jun; 10(7):578-95. PubMed ID: 20500149
[TBL] [Abstract][Full Text] [Related]
39. Re-Engineering RNA Molecules into Therapeutic Agents.
Egli M; Manoharan M
Acc Chem Res; 2019 Apr; 52(4):1036-1047. PubMed ID: 30912917
[TBL] [Abstract][Full Text] [Related]
40. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models.
Mangala LS; Rodriguez-Aguayo C; Bayraktar E; Jennings NB; Lopez-Berestein G; Sood AK
Methods Mol Biol; 2021; 2372():157-168. PubMed ID: 34417750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
